glp 1/gip What is GLP-1 and GIP? Dual-action weight loss (UK) GLP-1 and GIP receptor signaling

With the advent of these new drugs, it is likely that our specialty will see these patients and they may ask why there is this risk

During 2024 and 2025, the GLP-1 class was increasingly defined by expanded use cases and approvals, with existing drugs gaining indications including cardiovascular risk, sleep apnea and kidney disease

However, sensitivity analyses, which involved excluding individual studies, revealed that omitting one outlier study [22], characterized by substantial variability compared to the others, resulted in a significant increase in WL for the GLP-1RAs group (SMD = 0.82

doi:10.1210/jc.2018-00070 31

See more S.F